Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres
Discussion
Rheuma-VOR has shown an improvement in rheumatological care, patient-reported outcome parameters and cost savings by coordinating the cooperation of primary care physicians, rheumatologists and patients, in a nationwide approach. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Dreher, M., Witte, T., Hoeper, K., Assmann, G., Proft, F., Poddubnyy, D., Murawski, N., Triantafyllias, K., Grodd, M., Graf, E., Fichtner, U. A., Binder, H., Zeidler, J., Hoeper, J. R., Callhoff, J., Karberg, K., Trautwein, A., Tibyampansha, D., Wojnowski Tags: Open access, ARD Lay summaries, ARD, Early arthritis Source Type: research
Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies
Conclusions
Consistent with the warnings and precautions of the abatacept label, this analysis suggests a potential increase in NMSC risk with abatacept use compared with csDMARDs. No significant increase was observed compared with b/tsDMARDs, but the lower limit of the 95% CI was close to unity. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Simon, T. A., Dong, L., Suissa, S., Michaud, K., Pedro, S., Hochberg, M., Boers, M., Askling, J., Frisell, T., Strangfeld, A., Meissner, Y., Khaychuk, V., Dominique, A., Maldonado, M. A. Tags: Open access, ARD, Rheumatoid arthritis Source Type: research
Definition of rheumatoid arthritis flare based on SDAI and CDAI
Conclusion
We here provide novel definitions for flare in RA based on SDAI and CDAI, validated in two large independent real-world cohorts. In times of highly effective medications for RA, and consideration of their tapering, these definitions will be useful for guiding decision making in clinical practice and designing clinical trials. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Konzett, V., Kerschbaumer, A., Smolen, J. S., Kristianslund, E. K., Provan, S. A., Kvien, T. K., Aletaha, D. Tags: ARD, Rheumatoid arthritis Source Type: research
Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort
Conclusions
After long-term treatment-to-target, excess mortality occurred in patients with RA after>10 years since treatment start, with smoking as an important risk factor. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Heckert, S. L., Maassen, J. M., le Cessie, S., Goekoop-Ruiterman, Y. P. M., Güler-Yüksel, M., Lems, W., Huizinga, T. W., Bergstra, S. A., Allaart, C. F. Tags: Open access, ARD, Rheumatoid arthritis Source Type: research
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Fundamental insight gained over the last decades led to the discovery of cytokines as pivotal drivers of inflammatory diseases such as rheumatoid arthritis, psoriasis/psoriasis arthritis, inflammatory bowel diseases, atopic dermatitis and spondylarthritis. A deeper understanding of the pro-inflammatory and anti-inflammatory effects of various cytokines has prompted new cytokine-targeting therapies, which revolutionised the treatment options in the last years for patients with inflammatory disorders. Disease-associated immune responses typically involve a complex interplay of multiple cytokines. Therefore, blockade of one s...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Bonelli, M., Kerschbaumer, A., Kastrati, K., Ghoreschi, K., Gadina, M., Heinz, L. X., Smolen, J. S., Aletaha, D., O'Shea, J., Laurence, A. Tags: Open access, ARD Reviews Source Type: research
Rheumatology and Long COVID: lessons from the study of fibromyalgia
Rheumatology, such as other subspecialties, has both a unique perspective to offer as well as an evolving role to play in the global COVID-19 pandemic. Our field has already contributed meaningfully to the development and repurposing of many of the immune-based therapeutics which are now standard treatments for severe forms of the disease as well as to the understanding of the epidemiology, risk factors and natural history of COVID-19 in immune-mediated inflammatory diseases. Still in evolution is our potential to contribute to burgeoning research efforts in the next phase of the pandemic: the syndrome of postacute sequela...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Clauw, D. J., Calabrese, L. Tags: Open access, ARD, COVID-19 Viewpoint Source Type: research
Annals of the Rheumatic Diseases collection on osteoarthritis (2018-2023): hopes and disappointments
Over the past 5 years, we have witnessed significant advances in the field of osteoarthritis (OA) in terms of epidemiology, prognostic markers and therapeutic options. The year 2018 can be considered a breakthrough with the publication of a draft guidance by the Food and Drug Administration (FDA) designating OA as a serious disease.1 This is a revolution in the field, as this designation opens up the possibility for pharmaceutical companies to apply for accelerated approval during the development of a disease-modifying OA drug (DMOAD) based on yet-to-be defined surrogates. The Annals of the Rheumatic Diseases (ARD) has bee...
Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Berenbaum, F. Tags: ARD Editorials Source Type: research
Global, regional and national temporal trends in prevalence for musculoskeletal disorders in women of childbearing age, 1990-2019: an age-period-cohort analysis based on the Global Burden of Disease Study 2019
Conclusions
Although a favourable overall temporal trend (net drift) of MSK disorders prevalence in WCBA was observed over the last 30 years globally, there were 138 countries showing unfavourable rising trends, coupled with deteriorations in period/cohort risks in many countries, collectively raising concerns about timely realisation of the Targets of Sustainable Development Goal. Improvements in the MSK disorders-related prevention, management and treatment programmes in WCBA could decline the relative risk for successively younger birth cohorts and for all age groups over period progressing. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Cao, F., Li, D.-P., Wu, G.-C., He, Y.-S., Liu, Y.-C., Hou, J.-J., Ni, Q.-Y., Tao, L.-M., Jiang, Z.-X., Pan, H.-F. Tags: Editor's choice, ARD Lay summaries, ARD, Epidemiology Source Type: research
Data quality and patient characteristics in European ANCA-associated vasculitis registries: data retrieval by federated querying
Conclusions
In the largest reported AAV cohort-study, we federated patient registries using semantic web technologies and highlighted concerns about data quality. The comparison of patient characteristics, treatment and outcomes was hampered by heterogeneous recruitment settings. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Gisslander, K., Rutherford, M., Aslett, L., Basu, N., Dradin, F., Hederman, L., Hruskova, Z., Kardaoui, H., Lamprecht, P., Lichołai, S., Musial, J., OSullivan, D., Puechal, X., Scott, J., Segelmark, M., Straka, R., Terrier, B., Tesar, V., Tesi, M., Tags: Open access, ARD, Vasculitis Source Type: research
Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database
Conclusions
In life-threatening AAV, RTX has similar short-term effectiveness on mortality to IVCY. Although RTX might have a lower risk of fungal infections and pneumocystis pneumonia, the short-term renal prognosis might be inferior to IVCY. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Ishikawa, Y., Tokutsu, K., Nakayamada, S., Kuchiba, A., Fushimi, K., Matsuda, S., Tanaka, Y. Tags: ARD, Vasculitis Source Type: research
Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study
Conclusion
At 24 months, frequencies of relapse did not differ between the groups, and SAEs were less frequent in the reduced-dose group due to the lower event rate in the 6-month induction phase. The bias to myeloperoxidase-ANCA positivity (85.8%) in the trial population should be noted.
Trial registration number
NCT02198248. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Furuta, S., Nakagomi, D., Kobayashi, Y., Hiraguri, M., Sugiyama, T., Amano, K., Umibe, T., Kono, H., Kurasawa, K., Kita, Y., Matsumura, R., Kaneko, Y., Ninagawa, K., Hiromura, K., Kagami, S.-i., Inaba, Y., Hanaoka, H., Ikeda, K., Nakajima, H., for the LoV Tags: ARD Lay summaries, ARD, Vasculitis Source Type: research
Examining the biological pathways underlying clinical heterogeneity in Sjogrens syndrome: proteomic and network analysis
Conclusions
Our data provide clues to the pathways contributing to the glandular and non-glandular manifestations of SS and to potential therapeutic targets for different SS subtypes. In addition, our analysis highlights the need for further exploration of altered metabolism and mitochondrial dysfunction in the context of SS subtypes. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Berry, J. S., Tarn, J., Casement, J., Duret, P.-M., Scott, L., Wood, K., Johnsen, S.-J., Nordmark, G., Devauchelle-Pensec, V., Seror, R., Fisher, B., Barone, F., Bowman, S. J., Bombardieri, M., Lendrem, D., Felten, R., Gottenberg, J.-E., Ng, W.-F. Tags: ARD Sjo[x0308]gren ' s syndrome Source Type: research
L-arginine metabolism inhibits arthritis and inflammatory bone loss
Conclusion
Our study demonstrated that L-arginine ameliorates arthritis and bone erosion through metabolic reprogramming and perturbation of purine metabolism in osteoclasts. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Cao, S., Li, Y., Song, R., Meng, X., Fuchs, M., Liang, C., Kachler, K., Meng, X., Wen, J., Schlötzer-Schrehardt, U., Taudte, V., Gessner, A., Kunz, M., Schleicher, U., Zaiss, M. M., Kastbom, A., Chen, X., Schett, G., Bozec, A. Tags: Open access, ARD, Inflammatory arthritis Source Type: research
Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?
Conclusion
In randomised trials comparing GC bridging and no GC bridging, bridgers had a more rapid clinical improvement, fewer DMARD changes and similar late use of GC compared with non-bridgers. GC bridging per protocol resulted, as could be expected, in a higher cumulative GC dose over 2 years. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: van Ouwerkerk, L., Verschueren, P., Boers, M., Emery, P., de Jong, P. H. P., Landewe, R. B., Lems, W., Smolen, J. S., Huizinga, T. W., Allaart, C. F., Bergstra, S. A. Tags: ARD, Rheumatoid arthritis Source Type: research
Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis
Conclusion
ACR20 remains the most powerful discriminator between active treatment and placebo, especially when early discrimination is of primary interest. At the same time, our results support the selection of more stringent thresholds if later time points shall be evaluated, given their comparable discriminant but higher clinical face validity. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 2, 2024 Category: Rheumatology Authors: Konzett, V., Kerschbaumer, A., Smolen, J. S., Aletaha, D. Tags: ARD, Rheumatoid arthritis Source Type: research
